During 2006–2008, one quarter of patients with out-of-hospital cardiac arrest survived to discharge in one region of Norway.
As part of ongoing global efforts to monitor and improve survival from cardiac arrest, investigators prospectively compared survival rates for out-of-hospital cardiac arrest (OHCA) during 2001–2005 and 2006–2008 in a region of Norway. The study included 846 adult patients with OHCA of presumed cardiac etiology in whom resuscitation was attempted by emergency medical services (EMS).
In the first period, the local resuscitation algorithm was similar to the 2000 European Resuscitation Council guidelines, whereas in the second period, the algorithm differed from the 2005 guidelines in that it recommended 3 minutes between rhythm analyses and defibrillation attempts, with pulse checks 1 minute after rhythm analysis and, if no palpable pulse, intr…
Reviewing Author
DisclosuresConsultant/Advisory BoardPortola Pharmaceuticals, Inc.
Speaker’s BureauPeerView Institute for Medical Education
Grant/Research SupportAgency for Healthcare Research and Quality; CDC; NIH–National Center for Advancing Translational Sciences; NIH–National Institute of Allergy and Infectious Diseases (NIAID); NIH–NIAID–Antibacterial Resistance Leadership Group; Merck; Pfizer; Boehringer-Ingelheim; Shire; Portola Pharmaceuticals, Inc.; Novartis; bioMérieux; Siemens; Rapid Pathogen Screening; Magnolia; Stago; Innovative Biosensors; Molecular Detection, Inc.; Dyax Corp.; Trius Pharmaceuticals
DisclosuresConsultant/Advisory BoardPortola Pharmaceuticals, Inc.
Speaker’s BureauPeerView Institute for Medical Education
Grant/Research SupportAgency for Healthcare Research and Quality; CDC; NIH–National Center for Advancing Translational Sciences; NIH–National Institute of Allergy and Infectious Diseases (NIAID); NIH–NIAID–Antibacterial Resistance Leadership Group; Merck; Pfizer; Boehringer-Ingelheim; Shire; Portola Pharmaceuticals, Inc.; Novartis; bioMérieux; Siemens; Rapid Pathogen Screening; Magnolia; Stago; Innovative Biosensors; Molecular Detection, Inc.; Dyax Corp.; Trius Pharmaceuticals